Ceryvyn Therapeutics Ltd
OPT
Rank in Stocks
#31877
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Share Price
$0.00846342
Last synced: 2026-07-27
Market Cap
$11.27M
Change (1 day)
0.00%
Change (1 year)
-99.75%
Country
AU
Trade Ceryvyn Therapeutics Ltd (OPT)
Category
Healthcare
Market Capitalization of Ceryvyn Therapeutics Ltd(OPT)
Market Cap: $11.27M
As of October 2026 Ceryvyn Therapeutics Ltd has a market cap of $11.27M. This makes Ceryvyn Therapeutics Ltd the world's 31877th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Ceryvyn Therapeutics Ltd from 2020 to 2026
OPT compared with Top 5 Most Popular stocks
